![](https://investorshub.advfn.com/uicon/822788.png?cb=1664635735)
Monday, December 25, 2023 7:03:28 PM
I wish you a joyful and peaceful holiday season!
I regret to inform you that I ran your statement through the AI bs detector and it was identified as bs:
“This statement contains several speculative elements and assumptions, lacking factual accuracy or evidenced validity. Here are a few reasons why this statement is largely nonsensical and baseless:
1. **Lack of Context and Specificity**: The statement lacks clear context and specific information about the trial, the entities involved (like "Senti," "UCLA," "Powers," "NWBO").
2. **Speculative Nature**: The statement includes speculative assertions about motivations and actions of various parties involved in a clinical trial. These speculations are not backed by evidence and are presented as possibilities rather than established facts.
3. **Conspiracy Implications**: Suggesting that entities are deliberately not wanting a name to be associated with a trial due to fear of adverse events or for intellectual property negotiations implies a level of conspiracy which generally lacks credibility without substantial evidence.
4. **Clinical Trial Processes**: The statement misunderstands or oversimplifies the complex nature of clinical trials, particularly regarding control over adverse events and intellectual property negotiations. Clinical trials are subject to rigorous regulatory oversight, and adverse events are an expected part of the trial process, not a reason to exclude names or entities.
5. **Inherent Uncertainty in Clinical Research**: The statement that a larger trial would be required is one of the few reasonable elements, as it’s common in clinical research to require larger studies for definitive conclusions. However, this is framed within a speculative narrative.
Overall, the statement seems to mix elements of fact with speculation and unverified assertions about the intentions and actions of various parties involved in clinical research. Without clear evidence or a more detailed understanding of the context, the statement appears to be more of a personal conjecture than a scientifically or factually grounded assertion.”
—ChatGPT
![](http://investorshub.advfn.com/uimage/uploads/2023/12/23/fovbugiphy.gif)
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
![Bullish](/static/images/ih2-bull.png)
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM